2 Setups I’m Trading as Technology Names Are Bouncing
Here’s what’s on my radar and how I’m approaching the trades.
You've reached your free article limit
You've read 0 of 1 free Pro articles.
Market breadth is running close to even on Monday but all the major indexes are in the green with some rotational action back into the technology names that suffered the most last week. The Nasdaq 100 (QQQ) is up 1.7% and fully recovering its losses from Thursday. There is some weakness in retail, healthcare, consumer defensive, energy, and a few other places but that is offset by tech and AI names.
I’m already at high cash levels and making sure I’m not letting anything I’m holding slip too much. I’m also looking for some trades.
One small name I remounted this morning is NeoVolta (NEOV), which produced a 50% gain when I mentioned it about a week ago. It has pulled back to 50-day simple moving average support and I’m in for another trade.
Harrow on the Radar
Another name I want to highlight is Harrow (HROW). It has been on my radar for a while and I’m watching it closely as it moves into a consequential earnings report.
Harrow is an eye-care pharmaceutical company that develops and markets branded ophthalmic products for chronic eye conditions, including dry eye disease, glaucoma, cataracts, and retinal diseases.
The company’s flagship product is VEVYE, a treatment for dry eye disease that is projected to bring in over $100 million this year and account for roughly 28% of its total projected revenue. The rest of Harrow’s portfolio includes IHEEZO for cataract surgery, TRIESENCE for retinal conditions, and a growing set of branded ophthalmic products that just added BYOOVIZ on July 1.
Why the Stock Sold Off
HROW had two ugly gaps down on the daily chart this year. Both were driven by accounting and modeling issues rather than demand problems.
The first gap hit on March 3 when Q4 2025 revenue grew 36% but fell short of the company’s internal guidance. The second gap hit on May 12 when Q1 2026 missed on a $8 million one-time gross-to-net accounting adjustment. The Q1 issue was caused by an unexpected high-deductible patient mix and reporting lags rather than any softness in actual demand.
Management maintained full-year 2026 revenue guidance of $350 million to $365 million through both disruptions. They doubled the VEVYE sales force to 100 territories and implemented new pricing rules in mid-April to protect average selling prices. Q2 revenue guidance is $71 million to $81 million with sequential VEVYE growth expected.
Insider Buying Confirmed the Turnaround
When a stock drops on accounting noise, insider buying tells you whether management thinks the market has overreacted. In the days after the May selloff, Harrow insiders stepped up with several open-market purchases.
Harrow CEO Mark Baum bought 10,000 shares at $30.20 for a total of $302,000. CFO Andrew Boll bought 3,500 shares at $29.90 for $104,650. Directors Adrienne Graves and Lauren Silvernail each bought 1,000 shares.
When four senior insiders buy stock at the same time in the same window, they are telling the market they view the selloff as an overreaction to accounting noise rather than a change in the business trajectory.
New Catalysts Are Layered On
Harrow has three fresh commercial catalysts driving the second half setup.
VERKAZIA was re-launched in June. It is the only FDA-approved steroid-sparing therapy for pediatric vernal keratoconjunctivitis and addresses an unmet need in pediatric eye care. BYOOVIZ launched July 1 through a partnership with Samsung Bioepis. This one is a big deal because it puts Harrow into the $9 billion U.S. anti-VEGF retinal market for the first time. The IOPIDINE 1% J-Code became permanent on July 1, which means the product now has a permanent billing code that makes it easier for physicians to prescribe and get reimbursed.
The Technical Setup
HROW filled its second gap a few weeks ago and reclaimed the rising 200-day moving average in mid-June. Since then it has been consolidating in a tight range while it digests those gains. The consolidation is building the base for a potential move into the older March 3 gap.
Wall Street coverage remains positive. Per TipRanks, HROW has an overall bullish rating from seven covering analysts with seven Buy ratings and no Holds or Sells. The consensus median price target is impressive at $68.20 with the stock trading around $43. That is roughly 57% upside if the analyst estimates prove accurate. Cantor Fitzgerald’s Steve Seedhouse has the Street-high target at $88.
My Game Plan
I believe that optimism about Harrow will continue to build as investors contemplate the next report. There is a good base of support forming just above the 200-day simple moving average. I added to positions in my client accounts and will be looking to ramp it up more as conditions develop.
At the time of publication, Rev Shark was long NEOV and HROW.
Please note that due to factors including low market capitalization and/or insufficient public float, we consider NEOV to be micro-cap stocks. You should be aware that such stocks are subject to more risk than stocks of larger companies, including greater volatility, lower liquidity and less publicly available information, and that postings such as this one can have an effect on their stock prices.
